Re: Molecular Breast Imaging Under Threat by the Protecting Access to Medicare Act and ACR Appropriate Use Criteria

We read Dr Covington ’s concerns regarding the 2017 ACR Appropriateness Criteria® that categorizes molecular breast imaging as usually not appropriate for breast cancer screening [1]. As the lead authors of that guideline, we have re-reviewed and agree with the prose and the ratings based on the available evidence at the time. We have also read with interest the 2019 article “Comparative Benefit-to-Radiation Risk Ratio of Molecular Breast Imaging, Two-Dimensional Full-Field Digital Mammography With and Without Tomosynthesis, and Synthetic Mammography With Tomosynthesis” [2].

Source: Journal of the American College of Radiology : JACR - February 10, 2020 Category: Radiology Authors: Martha B. Mainiero, Linda Moy, Ana P. Lourenco Tags: Letter to the editor Source Type: research